Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine
Abstract
Article abstract Migraine aura is probably caused by cortical-spreading depression. No treatment for acute and severe migraine aura has been described previously. The effect of ketamine (25 mg intranasally) was studied in 11 patients with severe, disabling auras resulting from familial hemiplegic migraine. In five patients ketamine reproducibly reduced the severity and duration of the neurologic deficits, whereas in the remaining six patients no beneficial effect was seen. Ketamine offers, for the first time, a possible treatment option for severe and prolonged aura.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Launer LJ, Terwindt GM, Ferrari MD. The prevalence and characteristics of migraine in a population-based cohort: the GEM Study. Neurology 1999;53:537–542.
2.
Olesen J, Friberg L, Olesen TS, et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann Neurol 1990;28:791–798.
3.
Cutrer FM, Sorensen AG, Weisskoff RM, et al. Perfusion-weighted imaging defects during spontaneous migrainous aura. Ann Neurol 1998;43:25–31.
4.
Cao Y, Welch KM, Aurora S, Vikingstad EM. Functional MRI-BOLD of visually triggered headache in patients with migraine. Arch Neurol 1999;56:548–554.
5.
Lauritzen M, Hansen AJ. The effect of glutamate receptor blockade on anoxic depolarization and cortical spreading depression. J Cereb Blood Flow Metab 1992;12:223–229.
6.
Ophoff RO, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996;87:543–552.
7.
Strebel S, Kaufmann M, Maitre L, Schaefer HG. Effects of ketamine on cerebral blood flow velocity in humans. Influence of pretreatment with midazolam or esmolol. Anaesthesia 1995;50:223–228.
8.
Yassin M, Scholfield CN. NMDA antagonists increase recovery of evoked potentials from slices of rat olfactory cortex after anoxia. Br J Pharmacol 1994;111:1221–1227.
Information & Authors
Information
Published In
Copyright
© 2000.
Publication History
Received: October 14, 1999
Accepted: March 22, 2000
Published online: July 12, 2000
Published in print: July 12, 2000
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Hemiplegic migraine, Migraine Management, (353-365), (2024).https://doi.org/10.1016/B978-0-12-823357-3.00015-X
- Esketamine in depression: putative biomarkers from clinical research, European Archives of Psychiatry and Clinical Neuroscience, (2024).https://doi.org/10.1007/s00406-024-01865-1
- Visual Disturbances Spectrum in Pediatric Migraine, Journal of Clinical Medicine, 12, 8, (2780), (2023).https://doi.org/10.3390/jcm12082780
- Targeting Peripheral N-Methyl-D-Aspartate Receptor (NMDAR): A Novel Strategy for the Treatment of Migraine, Journal of Clinical Medicine, 12, 6, (2156), (2023).https://doi.org/10.3390/jcm12062156
- Evaluating migraine with typical aura with neuroimaging, Frontiers in Human Neuroscience, 17, (2023).https://doi.org/10.3389/fnhum.2023.1112790
- Ketamine Applications for Migraines: A Scoping Narrative Review, Annals Of Headache Medicine Journal, (2023).https://doi.org/10.30756/ahmj.2023.10.01
- Targeting CGRP pathways and aura: A peripheral site with a central effect, Cephalalgia, 43, 12, (2023).https://doi.org/10.1177/03331024231212895
- Real-world study of intranasal ketamine for use in patients with refractory chronic migraine: a retrospective analysis, Regional Anesthesia & Pain Medicine, 48, 12, (581-587), (2023).https://doi.org/10.1136/rapm-2022-104223
- A systematic review of the efficacy of ketamine for craniofacial pain, Canadian Journal of Pain, 7, 1, (2023).https://doi.org/10.1080/24740527.2023.2210167
- Migraine and treatment-resistant depression, Treatment-Resistant Depression Part B, (149-173), (2023).https://doi.org/10.1016/bs.pbr.2023.05.001
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.